Increased incidence of inflammatory bowel disease on etanercept in juvenile idiopathic arthritis regardless of concomitant methotrexate use

Autor: van Straalen, Joeri W., Krol, Roline, Giancane, Gabriella, Panaviene, Violeta, Ailioaie, Laura Marinela, Dolezalova, Pavla, Cattalini, Marco, Susic, Gordana, Sztajnbok, Flavio, Maritsi, Despoina, Constantin, Tamas, Sawhney, Sujata, Rygg, Marite, Oliveira, Sheila K., Nordal, Ellen Berit, Saad-Magalhaes, C, Rubio-Perez, Nadina, Jelusic, Marija, de Roock, Sytze, Wulffraat, Nico, Ruperto, Nicolino, Swart, Joost Frans, International Trials Org, Paediatric Rheumatology

Publikováno v: van Straalen JW, Krol R, Giancane G, Panaviene V, Ailioaie, Dolezalova P, Cattalini M, Susic G, Sztajnbok F, Maritsi D, Constantin T, Sawhney S, Rygg M, Oliveira SK, Nordal E, Saad-Magalhaes C, Rubio-Perez N, Jelusic M, de Roock S, Wulffraat N, Ruperto N, Swart JF, International Trials Org. Increased incidence of inflammatory bowel disease on etanercept in juvenile idiopathic arthritis regardless of concomitant methotrexate use. Rheumatology. 2021

Externí odkaz: https://hdl.handle.net/10037/24359